Is it time to rethink the Alzheimer's disease drug development strategy by targeting its silent phase?
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2018-01-01
|
| Series: | Neural Regeneration Research |
| Online Access: | http://www.nrronline.org/article.asp?issn=1673-5374;year=2018;volume=13;issue=2;spage=224;epage=225;aulast=Souchet |
| _version_ | 1818249422383874048 |
|---|---|
| author | Benoit Souchet Mickael Audrain Baptiste Billoir Laurent Lecanu Satoru Tada Jérôme Braudeau |
| author_facet | Benoit Souchet Mickael Audrain Baptiste Billoir Laurent Lecanu Satoru Tada Jérôme Braudeau |
| author_sort | Benoit Souchet |
| collection | DOAJ |
| first_indexed | 2024-12-12T15:36:14Z |
| format | Article |
| id | doaj.art-969a2558c79d4bc380bbf4beff5cff1a |
| institution | Directory Open Access Journal |
| issn | 1673-5374 |
| language | English |
| last_indexed | 2024-12-12T15:36:14Z |
| publishDate | 2018-01-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Neural Regeneration Research |
| spelling | doaj.art-969a2558c79d4bc380bbf4beff5cff1a2022-12-22T00:19:59ZengWolters Kluwer Medknow PublicationsNeural Regeneration Research1673-53742018-01-0113222422510.4103/1673-5374.226389Is it time to rethink the Alzheimer's disease drug development strategy by targeting its silent phase?Benoit SouchetMickael AudrainBaptiste BilloirLaurent LecanuSatoru TadaJérôme Braudeauhttp://www.nrronline.org/article.asp?issn=1673-5374;year=2018;volume=13;issue=2;spage=224;epage=225;aulast=Souchet |
| spellingShingle | Benoit Souchet Mickael Audrain Baptiste Billoir Laurent Lecanu Satoru Tada Jérôme Braudeau Is it time to rethink the Alzheimer's disease drug development strategy by targeting its silent phase? Neural Regeneration Research |
| title | Is it time to rethink the Alzheimer's disease drug development strategy by targeting its silent phase? |
| title_full | Is it time to rethink the Alzheimer's disease drug development strategy by targeting its silent phase? |
| title_fullStr | Is it time to rethink the Alzheimer's disease drug development strategy by targeting its silent phase? |
| title_full_unstemmed | Is it time to rethink the Alzheimer's disease drug development strategy by targeting its silent phase? |
| title_short | Is it time to rethink the Alzheimer's disease drug development strategy by targeting its silent phase? |
| title_sort | is it time to rethink the alzheimer s disease drug development strategy by targeting its silent phase |
| url | http://www.nrronline.org/article.asp?issn=1673-5374;year=2018;volume=13;issue=2;spage=224;epage=225;aulast=Souchet |
| work_keys_str_mv | AT benoitsouchet isittimetorethinkthealzheimersdiseasedrugdevelopmentstrategybytargetingitssilentphase AT mickaelaudrain isittimetorethinkthealzheimersdiseasedrugdevelopmentstrategybytargetingitssilentphase AT baptistebilloir isittimetorethinkthealzheimersdiseasedrugdevelopmentstrategybytargetingitssilentphase AT laurentlecanu isittimetorethinkthealzheimersdiseasedrugdevelopmentstrategybytargetingitssilentphase AT satorutada isittimetorethinkthealzheimersdiseasedrugdevelopmentstrategybytargetingitssilentphase AT jeromebraudeau isittimetorethinkthealzheimersdiseasedrugdevelopmentstrategybytargetingitssilentphase |